It is essential to inform your doctor if you are taking or have taken recently any of the following medications:
Carvedilol Krka intake with food, drinks, and alcohol
Avoid taking carvedilol simultaneously or immediately after taking grapefruit or grapefruit juice. Grapefruit or grapefruit juice may cause an increase in carvedilol's active ingredient in the blood and cause unpredictable effects. Also, avoid excessive and simultaneous or occasional consumption of alcohol, as alcohol affects carvedilol's effect.
Your doctor or pharmacist will inform you about the foods with which you should take the medication.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or if you think you may be pregnant, consult your doctor before using this medication.
Carvedilol is not recommended for use during pregnancy and breastfeeding.
Carvedilol may cause fetal death in the womb, as well as premature births. Additionally, adverse effects may occur in the fetus and newborn. After birth, the newborn has a higher risk of heart and lung problems.
Carvedilol passes into breast milk, so it is not recommended for use during breastfeeding.
Driving and operating machines
In some cases, this medication may make it difficult for you to drive or operate machines. This occurs especially when starting or changing treatment and when taking it with alcohol.
Carvedilol Krka contains saccharose and lactose
If your doctor has indicated that you have an intolerance to certain sugars, consult with them before taking this medication.
Follow exactly the administration instructions of this medication indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
Essential Hypertension
Adults:
Oral route. The recommended starting dose is 12.5 mg once a day for the first two days. Subsequently, the recommended dose is 25 mg once a day. If necessary, your doctor may increase the dose you receive (at intervals of at least two weeks) up to 50 mg once a day or in two doses of 25 mg each.
Older Adults:
Oral route. The recommended starting dose is 12.5 mg once a day, which has provided satisfactory control in some patients. If the response is not adequate, your doctor will adjust the dose (at intervals of at least two weeks).
Ischemic Cardiopathy
Adults:
Oral route. The recommended starting dose is 12.5 mg twice a day (total 25 mg per day) for the first two days. Subsequently, the recommended dose is 25 mg twice a day (total 50 mg per day). If necessary, your doctor may increase the dose you receive (at intervals of at least two weeks) up to 50 mg twice a day (total 100 mg per day).
Older Adults
Oral route. The maximum recommended dose for older adults is 50 mg administered in divided doses (twice a day).
Treatment of Symptomatic Congestive Heart Failure
Adults and Older Adults
Your doctor will tell you individually the dose you should take, closely monitoring you during the adjustment to higher doses.
In the case of using medications for heart diseases (digitalis) or blood pressure control (diuretics and/or ACE inhibitors) and before starting treatment with this medication, your doctor will adjust the amount of these types of medications you should take.
In any case, the recommended starting dose for treatment with this medication in symptomatic congestive heart failure is 3.125 mg twice a day (total 6.25 mg per day) for two weeks. If you tolerate this dose well, it can be increased later (at intervals of at least two weeks) up to 6.25 mg twice a day (total 12.5 mg per day). Your doctor may prescribe higher doses of this medication later (at least two weeks after).
If you weigh less than 85 kg, the maximum recommended dose is 25 mg twice a day (total 50 mg per day). If your weight is greater than 85 kg, the maximum recommended dose is 50 mg twice a day (100 mg per day).
Your doctor will indicate the duration of your treatment with this medication.
As a general rule, regardless of your disease, the withdrawal of this medication should be done gradually over a few days, or reduce the dose by half every three days.
Use in Children and Adolescents
This medication is not recommended for use in children and adolescents under 18 years due to the lack of sufficient data on safety and efficacy.
Guidelines for Correct Administration
Take the tablets with a sufficient amount of liquid, a glass of water.
If you have congestive heart failure (your heart has lost a little of its ability to pump blood and may produce difficulty breathing, weakness, and fluid accumulation), you should take this medication while eating, to avoid the feeling of dizziness when getting up.
Remember to take your medication.
The tablet can be split into equal doses.
If You Take More Carvedilol Krka Than You Should
If you take more carvedilol than you should, contact your doctor immediately or go to the nearest hospital. Bring the medication with you.
In case of overdose or accidental ingestion, consult the Toxicological Information Service, Telephone 91 562.04.20.
If You Forget to Take Carvedilol Krka
Do not take a double dose to compensate for the missed doses.
If You Interrupt Treatment with Carvedilol Krka
Treatment with carvedilol should not be interrupted abruptly, especially if you have ischemic cardiopathy, a disease that causes the heart not to pump blood well. Your doctor will gradually reduce the dose over a few days until you stop taking carvedilol completely.
If you have any other doubts about the use of this medication, consult your doctor or pharmacist.
Like all medicines, this medicine may cause side effects, although not everyone will experience them.
The side effects are classified as: very common (may affect more than 1 in 10 people), common (may affect up to 1 in 10 people), uncommon (may affect up to 1 in 100 people), rare (may affect up to 1 in 1,000 people), very rare (may affect up to 1 in 10,000 people) and unknown frequency (cannot be estimated from available data).
Infections and infestations
Common: Bronchitis, pneumonia, upper respiratory tract infections, urinary tract infections.
Nervous system disorders
Very common: Headache, dizziness, and weakness that are usually mild and occur mainly at the beginning of treatment.
Common: Lightheadedness, fainting, especially at the beginning of treatment.
Uncommon: Paresthesias (tingling sensation).
Mental and behavioral disorders:
Common: Depressed mood, depression.
Uncommon: Sleep disorders.
Unknown frequency: Hallucinations.
Cardiac disorders
Very common: Increased heart failure (the heart has lost some of its ability to pump blood).
Common: Bradycardia (decreased heart rate), fluid overload, increased blood volume in the body.
Uncommon: Atrioventricular (AV) block (heart problems), and angina pectoris (chest pain).
Unknown frequency: Sinus arrest (a condition that makes heartbeats very slow or stop), especially in elderly patients or patients with other heart rhythm problems.
Vascular disorders:
Very common: Low blood pressure.
Common: Postural hypotension (dizziness when standing up or changing body position), peripheral circulation disorders (cold hands and feet), increased symptoms in patients with intermittent claudication (increased pain in the legs when walking) or Raynaud's phenomenon (decreased blood flow to the fingers, hands, ears, and nose), hypertension.
Respiratory, thoracic and mediastinal disorders
Common: Asthma and breathing difficulties in predisposed patients, accumulation of fluid in the lungs.
Rare: Nasal congestion.
Gastrointestinal disorders
Common: Gastrointestinal disturbances with symptoms such as nausea, diarrhea, abdominal pain, indigestion, vomiting.
Uncommon: Constipation.
Rare: Dry mouth.
Skin and subcutaneous tissue disorders
Uncommon: Skin reactions (e.g. allergic exanthema, dermatitis, urticaria, itching, psoriasis, skin lesions of the type lichen planus).
Unknown frequency: Hair loss, severe cutaneous adverse reactions (e.g. toxic epidermal necrolysis, Stevens-Johnson syndrome), excessive sweating (hyperhidrosis).
Haematological and lymphatic system disorders
Common: Decreased red blood cell count in blood (anemia).
Rare: Decreased platelet count in blood (thrombocytopenia).
Very rare: Decreased white blood cell count in blood (leucopenia).
Hepatobiliary disorders
Very rare: Alterations in serum transaminases (changes in the amount of certain liver enzymes in the blood).
Ocular disorders
Common: Decreased tear production (dry eye), eye irritation, vision disturbances.
Renal and urinary disorders
Common: Acute renal failure (kidney not functioning well) and kidney function disorders in patients with diffuse vascular disease and/or altered kidney function.
Rare: Urination problems.
Unknown frequency: Urinary incontinence in women (disappears when stopping medication).
Immune system disorders
Very rare: Allergic reactions.
Musculoskeletal and connective tissue disorders
Common: Pain in the extremities.
Reproductive and breast disorders
Uncommon: Impotence.
Metabolism and nutrition disorders
Common: Worsening of blood sugar control in patients with diabetes (hyperglycemia, hypoglycemia), weight gain, increased blood cholesterol.
Unknown frequency: Possible manifestation of latent diabetes, or worsening of existing diabetes.
General disorders and administration site conditions
Very common: Fatigue.
Common: Pain, edema (fluid retention, swelling of the legs, ankles, and feet).
If you consider that any of the side effects you experience are severe or if you notice any side effect not mentioned in this leaflet, inform your doctor or pharmacist.
Reporting of side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicationout of the sight and reach of children.
This medication does not require any special temperature for conservation.
Do not use CarvedilolKrkaafter the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
Medicines should not be thrown down the drains or in the trash. Dispose of the packaging and medicines you no longer need at the SIGRE collection pointof the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need.This way, you will help protect the environment.
Composition ofCarvedilol Krka 25 mg:
Appearance of the product and content of the packaging
Carvedilol Krka 25 mg tablets are white, round, and scored on one face. They are presented in packaging of 28 and 500 tablets for oral administration.
Holder of the marketing authorization and responsible manufacturer
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
For further information about this medicinal product, please contact the local representative of the marketing authorization holder:
KRKA Farmacéutica, S.L., C/ Anabel Segura, 10, Pta. Baja, Oficina 1, 28108 Alcobendas, Madrid, Spain
Last review date of this leaflet:March 2024
Detailed information about this medicinal product is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) (http://www.aemps.gob.es/).
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.